Boston Scientific Acquires Penumbra for $14.5B: A Transformative Re-Entry Into Mechanical Thrombectomy and Neurovascular

The Deal at a Glance

On January 15, 2026, Boston Scientific Corporation (NYSE: BSX) and Penumbra, Inc. (NYSE: PEN) announced a definitive agreement under which Boston Scientific will acquire Penumbra in a cash and stock transaction valued at approximately $14.5 billion. The deal represents Boston Scientific's largest acquisition since its $25 billion Guidant buyout two decades ago, and marks a dramatic re-entry into the neurovascular and mechanical thrombectomy markets that the company exited in 2011 when it sold its neurovascular business to Stryker for $1.5 billion.

Penumbra stockholders can elect to receive $374 in cash or 3.8721 shares of Boston Scientific common stock per Penumbra share, subject to proration so that the total consideration is approximately 73% cash and 27% stock. Adam Elsesser, Penumbra's chairman and CEO, has indicated he will elect to receive Boston Scientific shares for all his holdings and is expected to join Boston Scientific's board of directors upon deal completion.

The transaction has been approved by the boards of directors of both companies and is expected to close in 2026, subject to Penumbra stockholder approval, regulatory clearances, and other customary closing conditions.

The Players

Boston Scientific Corporation

Boston Scientific is a global medical technology leader headquartered in Marlborough, Massachusetts, with products and technologies used in a wide range of interventional medical specialties. The company reported revenue of approximately $20.1 billion in 2025 and operates across major therapeutic areas including interventional cardiology, peripheral interventions, electrophysiology, neuromodulation, endoscopy, and urology.

Boston Scientific has been one of the most acquisitive companies in medtech. In the 18 months leading up to the Penumbra deal, the company completed or announced several significant transactions:

The Penumbra acquisition is a return to a market Boston Scientific knows well. In 2011, the company sold its neurovascular division (including the Wingspan stent system and Matrix coils) to Stryker for $1.5 billion as part of a portfolio streamlining. At the time, neurovascular was a smaller, less proven market. Fifteen years later, mechanical thrombectomy for ischemic stroke has become one of the most evidence-based and fastest-growing procedures in interventional medicine — and Boston Scientific is buying its way back in at scale.

Penumbra, Inc.

Penumbra, founded in 2004 and headquartered in Alameda, California, is the world's leading thrombectomy company. The company designs, manufactures, and markets innovative medical devices for the removal of blood clots from head to toe, with products spanning ischemic stroke, pulmonary embolism (PE), deep vein thrombosis (DVT), acute limb ischemia (ALI), and aneurysm treatment.

Penumbra reported full-year 2025 revenue of approximately $1.4 billion, representing 17.5% growth over the prior year. Fourth quarter 2025 revenue was $385.4 million, up 22.1% year-over-year, with US thrombectomy revenue growing 19.3% for the full year. Global embolization and access product revenue grew 37.0% in Q4, driven by a 42.7% increase in US sales. The company employs more than 4,500 people and markets its products in over 100 countries.

The company's financial profile shows improving profitability alongside rapid growth. Full-year 2025 operating income was $189.2 million with a 13.5% operating margin, and net income reached $177.7 million for the year. Q4 2025 operating income was $59.2 million with a 15.4% operating margin, demonstrating accelerating profitability.

Adam Elsesser has led Penumbra as CEO since its founding, building the company from a neurovascular startup into a multi-billion-dollar global thrombectomy platform. Under his leadership, Penumbra pioneered Computer Assisted Vacuum Thrombectomy (CAVT) technology and established a dominant position in mechanical clot removal across vascular territories.

Penumbra's Technology Platform

Computer Assisted Vacuum Thrombectomy (CAVT)

At the core of Penumbra's value proposition is its proprietary CAVT (Computer Assisted Vacuum Thrombectomy) technology. Unlike traditional aspiration thrombectomy, which relies on manual suction and operator technique, CAVT uses advanced algorithms to automatically detect blood clots and blood flow, coordinating aspiration with the Penumbra ENGINE that generates nearly pure vacuum.

CAVT systems feature dual clot detection algorithms using both pressure-based and flow-based sensing to differentiate between thrombus and blood. This automation reduces operator variability and allows consistent, high-power aspiration for rapid clot removal — a critical factor when treating time-sensitive conditions like stroke and pulmonary embolism.

Product Portfolio

Penumbra's portfolio spans three main segments, each representing a distinct growth opportunity:

Mechanical Thrombectomy (Peripheral)

The peripheral thrombectomy platform addresses venous thromboembolism (VTE) including pulmonary embolism and deep vein thrombosis, as well as acute limb ischemia. Key products include:

• Lightning Flash 3.0 — Launched in January 2026, the latest generation CAVT system for PE and VTE treatment. Features enhanced clot detection with increased sensitivity, enlarged tubing for large thrombus burdens, and an automated backflush feature to reduce friction from aspirated thrombus.
• Lightning Bolt 7 and Lightning Bolt 12 — Arterial CAVT systems for acute limb ischemia and peripheral arterial thrombus removal. Lightning Bolt 6X features a 6F-compatible design with Penumbra's TraX arterial-designed dilator for accurate vessel navigation. In Bolt Mode, Lightning Bolt 6X is five times faster than the prior-generation CAT6 system.
• Indigo Aspiration System — A broad platform for mechanical thrombectomy across arterial and venous territories.

Neurovascular

Penumbra's neurovascular portfolio covers ischemic stroke treatment and neuro embolization:

• RED Reperfusion Catheters — A range of aspiration catheters designed for rapid clot removal in acute ischemic stroke secondary to intracranial large vessel occlusions.
• Penumbra System — A fully integrated system designed specifically for mechanical thrombectomy in stroke, comprising the Penumbra ENGINE, catheters, and aspiration tubing. The Penumbra ENGINE generates nearly pure vacuum to power clot capture.
• 3D Revascularization Device — A next-generation thrombus removal device designed for use with RED, Penumbra JET, and ACE Reperfusion Catheters.

Embolization and Access

A growing segment for Penumbra, spanning vascular embolization for hemorrhage control and aneurysm treatment:

• Ruby Coil and POD Packing Coil — Embolization coils for peripheral and neurovascular applications.
• Swift Coil System — Neurovascular embolization coils.
• BENCHMARK Access System and MIDWAY Intermediate Catheters — Neurovascular access devices.

Clinical Evidence

The STORM-PE Landmark Trial

The STORM-PE (Study of Thrombectomy for Pulmonary Embolism) randomized controlled trial is perhaps the most important piece of clinical evidence validating Penumbra's CAVT technology. Published in Circulation and presented at the VIVA 2025 and TCT 2025 conferences, STORM-PE demonstrated that CAVT combined with anticoagulation achieved superior reduction in right heart strain compared to anticoagulation therapy alone in patients with acute intermediate-high-risk pulmonary embolism.

This was Level 1 evidence — the first randomized controlled trial to show that mechanical thrombectomy is superior to standard anticoagulation for PE treatment. The 90-day follow-up data confirmed that CAVT patients experienced significantly better functional outcomes compared to anticoagulation alone.

The implications are substantial. If CAVT becomes the standard of care for intermediate-high-risk PE based on Level 1 RCT evidence, the addressable patient population for mechanical thrombectomy expands dramatically — pulmonary embolism affects hundreds of thousands of patients annually in the US alone.

Additional Clinical Programs

Beyond STORM-PE, Penumbra has built a comprehensive clinical evidence base:

• STRIKE-PE — An ongoing study of CAVT as frontline therapy for PE, with interim data from 164 patients showing improved clinical and functional outcomes.
• STRIDE and STRIDE II — Trials evaluating Lightning Bolt CAVT technology for lower extremity acute limb ischemia. STRIDE I reported a 98.2% 30-day limb salvage rate and 3.4% mortality across enrolled patients, with STRIDE II expanding enrollment to up to 300 adults across 50 international sites.
• SIR 2026 data presentations — Seven separate datasets presented at the 2026 Society of Interventional Radiology meeting demonstrated that CAVT as frontline therapy improves clinical outcomes and reduces healthcare resource utilization, including shorter hospital stays and lower readmission rates.

The Strategic Rationale

Why Boston Scientific Is Buying Penumbra

The acquisition addresses several strategic imperatives for Boston Scientific simultaneously:

1. Re-entry into neurovascular at scale. Boston Scientific's 2011 exit from neurovascular now looks premature. The market for stroke intervention has been transformed by Level 1 evidence supporting mechanical thrombectomy, growing adoption of thrombectomy for large vessel occlusions, and expanding indications. Rather than rebuilding organically, Boston Scientific acquires the market leader.

2. Entry into mechanical thrombectomy. Thrombectomy for pulmonary embolism, DVT, and acute limb ischemia is one of the fastest-growing segments in vascular medicine. The STORM-PE trial provides Level 1 evidence that positions CAVT as a potential standard of care for PE, creating a large new market opportunity. Boston Scientific had no thrombectomy capability before this deal.

3. Complementary portfolio with minimal overlap. Boston Scientific's existing cardiovascular portfolio (coronary stents, structural heart, electrophysiology, peripheral interventions) has little direct overlap with Penumbra's thrombectomy and neurovascular products. This reduces antitrust risk and creates genuine cross-selling opportunities across shared hospital accounts.

4. Accelerating revenue growth. Penumbra's 17–22% growth rate significantly exceeds Boston Scientific's organic growth rate. The acquisition is immediately additive to Boston Scientific's top-line growth trajectory and becomes increasingly accretive to earnings over time.

5. International expansion opportunity. Penumbra generates a significant portion of revenue in the US. Boston Scientific's global commercial infrastructure across Europe, Asia Pacific, and emerging markets can accelerate Penumbra's international adoption, a synergy explicitly highlighted during Boston Scientific's TD Cowen conference presentation in March 2026.

Why Penumbra Accepted

For Penumbra, the transaction delivers several benefits:

• Premium valuation — At $374 per share, the deal represents a meaningful premium to Penumbra's trading price and reflects the value of the company's technology, clinical evidence, and growth trajectory.
• Global scale — Penumbra gains immediate access to Boston Scientific's global distribution, regulatory affairs, and market access capabilities, accelerating international growth that would take years to build organically.
• Manufacturing synergies — Boston Scientific indicated plans to leverage its Costa Rica manufacturing operations for Penumbra products, potentially improving margins through lower-cost production.
• Independence within scale — Per Boston Scientific's March 2026 investor presentation, Penumbra will operate as a standalone global business unit within Boston Scientific's cardiovascular/ICTx portfolio, retaining its commercial team and leadership.

Integration Plan

At the TD Cowen conference on March 3, 2026, Boston Scientific executives outlined the integration approach:

• Standalone business unit — Penumbra will operate as a standalone global business unit within Boston Scientific's cardiovascular and ICTx (Interventional Cardiology, Thrombectomy, and Vascular) portfolio, retaining its own commercial team and leadership structure.
• Supply chain leverage — Boston Scientific plans to leverage its existing manufacturing infrastructure, including its Costa Rica operations, to optimize Penumbra's production costs.
• Cross-selling — The combined company can cross-sell complementary products across neurovascular, thrombectomy, vascular, and interventional cardiology accounts, many of which share the same hospital call points.
• International expansion — Penumbra products will be distributed through Boston Scientific's established international commercial network, significantly accelerating geographic expansion.

The Competitive Landscape

Who Loses

The Penumbra acquisition reshapes the competitive dynamics in several markets:

Neurovascular (stroke): The primary competitors are Stryker (which bought Boston Scientific's old neurovascular business), Medtronic (with its Solitaire stent retriever), and Phenox. Boston Scientific re-enters this market as a major player rather than a niche participant.

Mechanical thrombectomy (peripheral): Competitors include Inari Medical (now part of Stryker), which markets the FlowTriever system for PE and the ClotTriever for DVT. The Boston Scientific–Penumbra combination creates a thrombectomy powerhouse that matches or exceeds Stryker/Inari's capabilities.

Embolization: Competitors include Medtronic, Stryker, Terumo, and MicroVention. Penumbra's Ruby and Swift coil platforms, combined with Boston Scientific's interventional cardiology distribution, strengthen the combined company's position in this growing market.

The Broader M&A Context

The Penumbra deal continues a pattern of large-cap medtech consolidation in vascular care:

The pattern is clear: the largest medtech companies are investing aggressively in vascular intervention, with thrombectomy emerging as a key competitive battleground. Stryker's $4.9 billion acquisition of Inari Medical in 2025 and Boston Scientific's $14.5 billion acquisition of Penumbra in 2026 represent the two sides of an arms race in clot removal technology.

Market Context

Mechanical Thrombectomy: A Market in Transformation

The global mechanical thrombectomy market is undergoing a fundamental expansion driven by clinical evidence, growing procedural volumes, and expanding indications:

1. Stroke thrombectomy is now standard of care. Multiple randomized controlled trials (MR CLEAN, ESCAPE, EXTEND-IA, SWIFT PRIME, REVASCAT) published between 2015 and 2018 established mechanical thrombectomy as the standard treatment for acute ischemic stroke caused by large vessel occlusions. The evidence base has only strengthened since, expanding to include extended time windows and broader patient populations.

2. Pulmonary embolism is the next frontier. PE affects 300,000–600,000 people annually in the US, with 60,000–100,000 deaths. The STORM-PE trial's Level 1 evidence supporting CAVT over anticoagulation alone has the potential to transform PE treatment, creating a large new procedural market for mechanical thrombectomy.

3. Venous thrombectomy is growing. Treatment of DVT and other venous thrombotic conditions with mechanical devices is gaining clinical acceptance, particularly for patients with high thrombus burden or contraindications to prolonged anticoagulation.

4. Acute limb ischemia is an underserved market. ALI represents a significant clinical need with limited treatment options. Penumbra's STRIDE trial demonstrated excellent outcomes (98.2% 30-day limb salvage rate), supporting broader adoption.

Financial Analysis

Valuation

At $14.5 billion, Boston Scientific is paying approximately 10.4x Penumbra's 2025 revenue of $1.4 billion. This is a premium multiple, but reflects several factors:

• Growth premium — Penumbra's 17–22% growth rate commands a premium to the medtech sector average of 5–8% growth.
• Market position — Penumbra holds a leading or dominant position in multiple high-growth segments (stroke thrombectomy, PE thrombectomy, neurovascular embolization).
• Clinical moat — The STORM-PE Level 1 evidence creates a competitive advantage that is difficult to replicate quickly.
• Platform value — The CAVT technology platform is extensible to new indications and geographies, supporting long-term growth beyond current product lines.

Financing and Balance Sheet Impact

Boston Scientific is financing the approximately $11 billion cash portion through new debt issuance. While the company had a strong balance sheet before the deal (debt-to-equity of 0.51 and current ratio of 1.62), the acquisition will increase leverage significantly. Analysts project adjusted EBITDA leverage of approximately 3.3x by end of 2026. Boston Scientific will need to execute a disciplined deleveraging strategy to maintain financial flexibility for future investments.

The deal is expected to be $0.06–$0.08 dilutive to adjusted earnings per share in the first full year following closing, neutral to slightly accretive in the second year, and increasingly accretive thereafter as revenue synergies materialize and cost efficiencies are realized.

What This Means for the Industry

For Vascular Device Companies

1. The vascular intervention market is consolidating rapidly. With Stryker acquiring Inari and Boston Scientific acquiring Penumbra, the thrombectomy market is becoming a two-horse race. Smaller thrombectomy companies may face increasing competitive pressure and may need to find niche positioning or consider strategic partnerships.

2. Clinical evidence drives M&A premiums. Penumbra's STORM-PE Level 1 data was a significant driver of its $14.5 billion valuation. Companies investing in randomized controlled trials are building the clinical assets that command premium acquisition prices.

3. The neurovascular market is now a three-horse race. With Stryker, Medtronic, and now Boston Scientific all holding major neurovascular portfolios, the competitive intensity in stroke intervention will increase, potentially benefiting hospitals through more competitive pricing but also driving faster innovation.

For Hospitals and Health Systems

1. Broader product portfolios from fewer vendors. Hospital procurement teams will increasingly negotiate with large platform companies (BSX + Penumbra, Stryker + Inari) that can offer bundled vascular device portfolios, potentially simplifying supply chain management but also raising concerns about vendor consolidation.

2. More investment in thrombectomy training and infrastructure. Boston Scientific's commercial investment in Penumbra's products will likely expand the number of hospitals and physicians trained in mechanical thrombectomy procedures, supporting broader patient access.

For Startups and Investors

1. Thrombectomy remains a hot investment thesis. The $14.5B Penumbra and $4.9B Inari valuations confirm that thrombectomy technology commands premium M&A prices, validating venture investment in the space.

2. Adjacent vascular technologies will be the next targets. With thrombectomy platforms secured, acquirers may look for complementary technologies in embolization, vascular access, imaging guidance, and AI-powered treatment planning.

3. The tuck-in model is giving way to platform acquisitions. Boston Scientific's $14.5 billion bet on Penumbra shows that large-cap medtech companies are willing to make transformational acquisitions, not just small tuck-in deals, when the strategic fit and growth profile are compelling.

Key Takeaways

• Boston Scientific announced a $14.5 billion acquisition of Penumbra on January 15, 2026 — its largest deal since Guidant two decades ago — to re-enter the neurovascular market it exited in 2011 and gain scaled entry into mechanical thrombectomy
• Penumbra reported FY2025 revenue of approximately $1.4 billion (17.5% YoY growth) with Q4 revenue of $385.4 million (22.1% growth), making it the world's leading thrombectomy company
• The transaction values each Penumbra share at $374, with consideration structured as approximately 73% cash and 27% Boston Scientific stock; Adam Elsesser will join BSX's board upon close
• Penumbra's CAVT technology platform, including the Lightning Flash 3.0 and Lightning Bolt systems, uses proprietary algorithms for automated clot detection and removal across stroke, PE, DVT, and ALI
• The STORM-PE randomized controlled trial provided Level 1 evidence that CAVT with anticoagulation is superior to anticoagulation alone for intermediate-high-risk pulmonary embolism — potentially transforming PE treatment
• Penumbra will operate as a standalone global business unit within Boston Scientific's cardiovascular/ICTx portfolio, with cross-selling and international expansion as key synergy drivers
• The acquisition reflects a broader consolidation trend in vascular medtech, following Stryker's $4.9B acquisition of Inari Medical and Boston Scientific's own $1.5B MiRus investment
• The deal is expected to close in 2026 subject to stockholder approval and regulatory conditions, with an expected financial impact of $0.06–$0.08 dilutive to adjusted EPS in the first full year, neutral to accretive thereafter